Research programme: herpes simplex virus DNA replication inhibitors - ViRAZE
Latest Information Update: 11 Aug 2016
At a glance
- Originator University of Pennsylvania
- Developer ViRAZE
- Class Small molecules
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Herpes simplex virus infections